<DOC>
	<DOCNO>NCT01153334</DOCNO>
	<brief_summary>Objectives : An investigator-initiated , double-blind , randomize , placebo-controlled , multi-center study evaluate efficacy early intensive rosuvastatin therapy ( rosuvastatin 40 mg pre-PCI load 7 day post PCI 10 mg daily thereafter ) versus low dose conventional statin therapy ( placebo pre-PCI load rosuvastatin 10 mg daily primary PCI ) infarct size measure cardiac MRI clinical outcome STEMI patient undergo primary percutaneous coronary intervention ( PCI ) . Hypothesis : The infarct size early high dose rosuvastatin group small control patient treat low conventional statin therapy .</brief_summary>
	<brief_title>Efficacy Early Intensive ROsuvastatin Therapy Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention ( ROSEMARY Trial )</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Patient symptom acute myocardial infarction within 12 hour STsegment elevation 1 mm least two contiguous lead EKG new onset LBBB . 2 . Male female 20 year age 3 . Signed write informed consent participate study 1 . Congestive heart failure ( NYHA Class III IV ) LVEF &lt; 35 % . 2 . Clinically significant heart disease require CABG , cardiac transplantation , surgical repair and/or replacement course study . 3 . Previous MI CABG 4 . Known serious hypersensitivity reaction statin , antiplatelet agent ( aspirin clopidogrel ) , heparin . 5 . Known familial hypercholesterolemia 6 . Known skeletal muscle disease 7 . Known active liver disease hepatitis liver cirrhosis ( except fatty liver ) 8 . Renal failure ( Cr &gt; 2.0 mg/dL ) 9 . Secondary cause hyperlipoproteinemia : uncontrolled primary hypothyroidism , and/or nephrotic syndrome 10 . Noncardiac comorbidity life expectation &lt; 1 year 11 . Contraindications CMRI ( eg , implant pacemaker cardiac defibrillator , claustrophobia , etc . ) 12 . Pregnant lactate woman woman childbearing potential 13 . Participation investigational drug device study within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>